Pfizer Pays More Today, but GSK Has More Dividend Headroom

Pfizer and GSK present income investors with a familiar tradeoff: more yield now or more room to absorb setbacks.

The source analysis calculated that Pfizer paid about $9.79 billion in dividends from $10.98 billion of trailing free cash flow through June 2026, an 89% ratio. GSK paid about £2.67 billion from £6.90 billion of free cash flow, or 39%. Those figures use company data but remain sensitive to working-capital movements and the definition of free cash flow.

Pfizer's 6.3% indicated yield is higher than GSK's 4.1%, and management has said it expects to maintain the dividend. The pressure comes from patent expirations and declining COVID-product revenue. Pfizer is counting on newer launches, acquisitions and cost savings to rebuild growth while continuing a large cash distribution.

GSK reset its dividend earlier in the decade, leaving more coverage today. It expects a 70 pence dividend for 2026 and a progressive policy afterward. Specialty medicines and vaccines have supported growth, but the company also faces loss of exclusivity for dolutegravir near the end of the decade. Its acquisition activity increased net debt, adding another call on cash.

Currency matters for U.S. investors because GSK declares its dividend in pounds. Clinical failures, regulatory delays and acquisition integration can also alter either company's cash profile quickly.

On current coverage, GSK has the wider margin for error. Pfizer offers more immediate income and more upside if its pipeline replaces lost revenue on schedule. Investors should update the comparison after each earnings release using normalized free cash flow, net debt and the revenue at risk from upcoming patent expirations.